Covestor’s Y-mAbs Therapeutics YMAB Stock Holding History

Covestor’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16	Closed	–	–	2478
2021 Q4	$0	Buy	+16	New	+$342	﹤0.01%	2323

Other funds holding YMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Covestor's YMAB Position: Q1 2022 in Review

Covestor sold out of Y-mAbs Therapeutics (YMAB) in Q1 2022, closing a stake of 16 shares.

Covestor first reported a position in YMAB in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 88 funds tracked by Wall St. Rank hold YMAB as of Q1 2022.

Covestor reported no remaining Y-mAbs Therapeutics position as of Q1 2022 after selling out during the quarter.
Covestor sold 16 Y-mAbs Therapeutics shares in Q1 2022.
Covestor first reported a position in Y-mAbs Therapeutics in Q4 2021 and held it in 1 quarter.
Covestor's Y-mAbs Therapeutics position peaked at $0 in Q4 2021.
88 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2022.

Based on Covestor's 13F filing for Q1 2022, filed 13 May 2022.